Fig.5 TRPA1 deficiency reduces macrophage infiltration in lesions. (A) The expression of F4/80, iNOS, CD206 and Gapdh using Western blot. (B) Immunofluorescence staining images of F4/80 (red) and DAPI (blue; ×40.
3.5 Administration TRPA1 antagonists HC030031 mitigates skin inflammation andscratching behavior in DNCB-induced AD mouse model
To eliminate the possibility of compensatory mechanisms in the KO animals and explore whether selective TRPA1 antagonists HC030031 can be used as a targeted therapy for DNCB-induced AD. Experiments were carried out involving pre-treatment with the HC030031. Wild-type (WT) mice received an intraperitoneal injection of HC-030031 (TRPA1 receptor analog, 100mg/kg, ApexBio, USA). Applying HC-030031 prior to DNCB challenge alleviated atopic symptoms, ear thickness and scratching behavior (Figure 6A-6C ). At the same time, HC-030031 recovered histological abnormalities (Figure 6D-6E). Our experiments with TRPA1 antagonists were similar to the observed profile in TRPA1 KO mice. Altogether, the obtained results show that anti-TRPA1 represents a potential therapeutic target for AD disease.